Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Trinity Biotech Uni-Gold Recombigen

This article was originally published in The Gray Sheet

Executive Summary

Rapid HIV antibody blood test gains CLIA waiver for use with finger stick whole blood samples, an indication approved by FDA earlier this year (1"The Gray Sheet" Oct. 4, 2004, In Brief). The waiver gives Trinity access to the public health market, which the firm estimates to be about three times the size of the hospital lab segment, where the test currently competes. OraSure's OraQuick Advance oral fluid test is the only other CLIA-waived, FDA-approved rapid HIV test for the public health market (2"The Gray Sheet" Oct. 25, 2004, In Brief)...

You may also be interested in...

Trinity Biotech Uni-Gold Recombigen

Rapid HIV antibody test gains FDA go-ahead for use with fingerstick whole blood, boosting its marketing potential "significantly" beyond approvals received in 2003 covering serum, plasma and whole blood, Trinity says. The firm has applied to expand its venous whole-blood CLIA waiver to include the new indication...

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.

In A Bizarre Move, Trump Orders GM To Make Ventilators – Even Though The Auto Giant Already Is

President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts